Is Cybin Inc. Common Stock (HELP) a Buy, Sell, or Hold?
Cybin Inc. Common Stock
NASDAQ:HELP
$6.68 USD
-$0.02 (-0.3%)
- Volume
- 690.79K
- Average Volume
- 1.25M
- Market Capitalization
- $334.24M
- P/E Ratio
- -1.61
- Dividend Yield
- 0.00%
- Price Target
- $18.50
- Year High
- $9.12
- Year Low
- $3.76
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.52
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael F. Cola |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HELP |
| CUSIP | 23256X407 |
| CIK | 0001833141 |
| Web | http://www.cybin.com |
| Phone | 908 764 8385 |
| Currency | USD |
| Employees | 100 |
| Country | CA |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.52 |
| Quick Ratio | 9.52 |
| Cash Ratio | 8.12 |
Sales & Book Value
| Annual Sales | $-44.68M |
| Price / Sales | 0.00 |
| Cash Flow | -2.51 |
| Price / Cash Flow | -1.27 |
| Price / Book | 1.44 |
Price Target and Rating
| Average Stock Price Forecast | $18.50 |
| High Stock Price Forecast | $22.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | -63.89% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.23 |
| Trailing P/E Ratio | -1.61 |
| PEG Ratio | -0.07 |
| P/E Growth | -0.07 |
| Net Income | $-147.05M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -72.37% |
| Return on Assets | -58.36% |
Financials Score
| AltmanZ Score | 7.98 |
| Piotroski Score | 4.00 |
| Working Capital | 230.31M |
| Total Assets | 350.27M |
| Ebit | -153.29M |
| Market Cap | 486.41M |
| Total Liabilities | 27.02M |
Poll Results
About Cybin Inc. Common Stock (NASDAQ:HELP) Stock
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder. ...
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
2026-07-12 09:06:12
I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP's lead asset HLP003, an oral deuterated psilocin analog for adjunctive MDD, shows compelling Phase 2 efficacy, FDA Breakthrough Therapy Designation, and a differentiated clinical profile. Current valuation (~$269M EV, ~$207M pro forma cash) under-credits the probability-weighted value of HLP003, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds.
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
2026-06-29 07:40:00
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE, for potential U.S. FDA New Drug Application in 2028 1,2,3 -
Cybin: A Speculative Bet On Their Pivotal Depression Readout
2026-06-27 10:40:00
Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don't have financial debt. So, they should have enough resources to reach this important milestone later this year.
2026-06-26 09:30:00
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026. NEW YORK and TORONTO, June 26, 2026 /PRNewswire/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule.
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
2026-06-25 09:27:58
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the "Common Shares") at an offering price of US$4.
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
2026-06-25 09:27:00
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share for aggregate gross proceeds of US$50 million (the “Offering”).
Helus Pharma™ Announces US$50 Million Underwritten Offering
2026-06-24 06:01:00
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
2026-06-24 06:00:00
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment -
Frequently Asked Questions
-
What is the current Cybin Inc. Common Stock (HELP) stock price?
-
Cybin Inc. Common Stock(NASDAQ:HELP) stock price is $6.68 in the last trading session. During the trading session, HELP stock reached the peak price of $9.12 while $3.76 was the lowest point it dropped to. The percentage change in HELP stock occurred in the recent session was --0.3% while the dollar amount for the price change in HELP stock was -$-0.02.
-
HELP's industry and sector of operation?
-
The NASDAQ listed HELP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HELP?
-
Douglas Sommerville | Chief Pharmaceutical Strategist
Allison House-Gecewicz | Senior Vice President of Clinical Operations
Lori Challenger | Chief Compliance, Ethics & Administrative Officer
Sara Brittany Somerset | Chief Communications Officers
Gabriel Fahel | Chief Legal Officer & Corporate Secretary -
How many employees does HELP have?
-
Number of HELP employees currently stands at 100. HELP operates from 100 King Street West, Toronto, ON M5X 1C9, CA.
-
Link for HELP official website?
-
Official Website of HELP is: http://www.cybin.com
-
How do I contact HELP?
-
HELP could be contacted at phone #908 764 8385 and can also be accessed through its website. HELP operates from 100 King Street West, Toronto, ON M5X 1C9, CA.
-
How many shares of HELP are traded daily?
-
The average number of HELP shares traded daily for last 3 months was 1.25M.
-
What is the market cap of HELP currently?
-
The market value of HELP currently stands at $334.24M with its latest stock price at $6.68